Business
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepati
About this update from Hansoh Pharmaceutical Group Company Limited
[{"type":"image","alt":"Regeneron Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Regeneron Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/dd48a84a10e2c569a1750589118f2d19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OMbrbjdR7YYzdW3N_PREZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/dd48a84a10e2c569a1750589118f2d19","width":300,"height":47}},"lazy":false},{"type":"text","content":"Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48","length":82,"tagName":"p"},{"type":"text","content":"Regeneron’s global Phase 3 registrational program to be initiated later this year","length":81,"tagName":"p"},{"type":"text","content":"TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepatide is a novel dual GLP-1/GIP receptor agonist for which Regeneron has exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau as part of a strategic in-licensing agreement.","length":563,"tagName":"p"},{"type":"text","content":"The Phase 3 randomized, double-blind, placebo-controlled trial conducted by Hansoh enrolled 604 adults across 33 clinical sites in mainland China and evaluated once-weekly olatorepatide compared to placebo for 48 weeks. The study assessed four cohorts, including 5 mg, 10 mg or 15 mg olatorepatide and placebo. The trial met its co-primary endpoints, demonstrating that olatorepatide compared to placebo led to a statistically significant reduction in body weight from baseline, and also a statistically significant greater proportion of participants who achieved at least 5% weight loss at 48 weeks. Participants treated with olatorepatide achieved up to a 19% mean weight loss from baseline at week 48. Responder analyses showed that up to 97% of participants achieved ≥5% weight loss at week 48.","length":798,"tagName":"p"},{"type":"text","content":"Olatorepatide demonstrated a favorable gastrointestinal tolerability in ...
More updates from Hansoh Pharmaceutical Group Company Limited